IFOM, The Firc Institute of Molecular Oncology, Milano, Italy.
Institute of Medical Biology (IMB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
EMBO J. 2021 Nov 15;40(22):e108225. doi: 10.15252/embj.2021108225. Epub 2021 Oct 4.
Cells with blocked microtubule polymerization are delayed in mitosis, but eventually manage to proliferate despite substantial chromosome missegregation. While several studies have analyzed the first cell division after microtubule depolymerization, we have asked how cells cope long-term with microtubule impairment. We allowed 24 clonal populations of yeast cells with beta-tubulin mutations preventing proper microtubule polymerization, to evolve for ˜150 generations. At the end of the laboratory evolution experiment, cells had regained the ability to form microtubules and were less sensitive to microtubule-depolymerizing drugs. Whole-genome sequencing identified recurrently mutated genes, in particular for tubulins and kinesins, as well as pervasive duplication of chromosome VIII. Recreating these mutations and chromosome VIII disomy prior to evolution confirmed that they allow cells to compensate for the original mutation in beta-tubulin. Most of the identified mutations did not abolish function, but rather restored microtubule functionality. Analysis of the temporal order of resistance development in independent populations repeatedly revealed the same series of events: disomy of chromosome VIII followed by a single additional adaptive mutation in either tubulins or kinesins. Since tubulins are highly conserved among eukaryotes, our results have implications for understanding resistance to microtubule-targeting drugs widely used in cancer therapy.
细胞微管聚合受阻会在有丝分裂中延迟,但最终尽管染色体严重错分,仍能增殖。虽然有几项研究分析了微管解聚后的第一次细胞分裂,但我们还想知道细胞如何长期应对微管损伤。我们让 24 个带有阻止微管聚合β-微管蛋白突变的酵母克隆群体进化了约 150 代。在实验室进化实验结束时,细胞重新获得了形成微管的能力,并且对微管解聚药物的敏感性降低。全基因组测序鉴定出了反复突变的基因,特别是微管蛋白和驱动蛋白,以及染色体 VIII 的广泛重复。在进化之前重现这些突变和染色体 VIII 三体,可以确认它们使细胞能够补偿β-微管蛋白中的原始突变。大多数鉴定出的突变并没有完全丧失功能,而是恢复了微管的功能。对独立群体中耐药性发展的时间顺序进行分析,反复揭示了相同的一系列事件:染色体 VIII 的三体性,随后是微管蛋白或驱动蛋白中的单个额外适应性突变。由于微管蛋白在真核生物中高度保守,我们的研究结果对理解广泛用于癌症治疗的微管靶向药物的耐药性具有重要意义。